Key Takeaways
- Double-digit growth with a clean core: Revenue grew 15%, but stripping out a ~4–5% favorable base effect from last year's CMO disruption, sustainable comparable growth was a healthy 9–10%, driven by broad-based outperformance across all therapy areas.
- Innovation portfolio is scaling fast: New products launched in the last ~3 years now contribute 7% of total revenue, up from ~4% last year, adding roughly 4 percentage points to headline growth.
- Margins held despite a deliberate investment surge: EBITDA grew 17% and margins expanded, absorbing a front-loaded, Q1-specific promotional push ahead of the seasonally critical September quarter.
- The oncology bet is beginning to pay: The oncology business touched a ₹10 crores/month run-rate, with 263 patients in Q1 and a dedicated team reaching productivity in under 11 months, just as a third launch (Blenrep) is imminent.
- What to watch next quarter: Whether the acute-season uptick materializes as expected, the pace of opex ratio normalization back to historical trends, and the initial market reception for the Blenrep launch.
Top-Line Growth & Demand Environment
- Broad-based industry tailwind: The Indian pharma market grew ~13.5% in Q1 with balanced contributions from volume (~2%), price, and new introductions; both acute and chronic segments grew, favoring GSK's acute-skewed portfolio and its recent chronic forays.
- Outperformance across the board: GSK grew faster than the external market in every therapy area and sub-therapy where it operates, with IQVIA efficiency indices at 105–106 for all General Medicines brands, signaling a robust underlying business turnaround.
- Geographic and prescriber balance: Growth was evenly distributed across metros, Tier 1, Tier 2, and rural markets, and balanced across specialists, super-specialists, and general practitioners.
- Volume-price-new intro mix: Q1 growth was driven by a blend of ~3–3.5% volume, ~6% price, and the balance from new introductions; the innovation portfolio's contribution to the mix is a structural shift from near-zero a year ago.
- Supply chain recovery complete: The worst of the CMO supply issues is behind; management stress-tested the entire supply chain and confirmed underlying adjusted growth remains double digit.
- Q2 acute season tracking well: Trends from June and the last 4–6 weeks are indicative of a seasonal upswing; management expects Q2 to be in line with expectations.
Akshikar: "I think it's safe to say that the worst is behind us. I think we learned, we've used those learnings from the unfortunate incident that we had at one CMO to stress-test the entire supply chain."
Innovation Portfolio & Specialty Pipeline
- Innovation sales scale: Innovation sales reached 7% of total revenues vs ~4% last year, contributing ~4 percentage points of headline growth; the portfolio transformation toward IP-protected, higher-growth assets remains on track.
- Specialty respiratory gaining traction: Nucala new patient numbers doubled YoY from ~50–60 to ~100–120 per month, driven by the impact of Mepolizumab for severe eosinophilic asthma; Trelegy Ellipta continues to grow in units and hold significant market share despite 10–12 generic launches of the Umeclidinium molecule, with the Ellipta device acting as an innovation differentiator.
- Oncology business scaling: Zejula and Jemperli touched 263 patients in Q1, with the business reaching a ₹10 crores/month run-rate; a team of 40–45 people achieved productivity in under 11 months; Zejula is already among the top five PARP inhibitors in a fragmented market, and Jemperli patients are achieving complete remission with 12–13 cycles.
- Blenrep launch imminent: The antibody drug conjugate for second-line refractory relapsed multiple myeloma has received marketing authorization and CDSCO/DCGI approval; launch expected in the next 2–3 months, most probably in Q2.
- Bepirovirsen on the horizon: India was part of the global B-Well clinical trial; results presented at EASL Congress position it as a breakthrough for functional cure in chronic hepatitis B, a disease affecting over 4 crore patients in India; launch still 3–4 quarters away at least, with fundamental commercial strategy work underway.
- Arexvy category creation ahead: Marketing authorization received for the first adult RSV vaccine in India; management describes the opportunity as massive but expects a need to build fundamental understanding of RSV, not immediate mass adoption.
- Global clinical trials in India: Over the last 18–24 months, many global clinical trials have been brought into India, reducing the lag for drug launch timelines.
Akshikar: "The concept of functional cure is almost non-existent in chronic hepatitis B. Now when you look at a country like ours apart from some other countries in Asia, the burden of disease is the highest here. I mean we have more than 4 crore patients who have chronic hepatitis B."
Vaccines
- Private market leadership maintained: The overall vaccines business held market leadership in the private segment; pediatric vaccines continued their leadership position.
- Shingrix growth accelerating: The adult shingles vaccine grew ~65% in Q1, selling upwards of 45,000–50,000 doses quarterly, driven by HCP engagements, improving adult vaccination ecosystem, and unmet need among 50+ adults with comorbidities like cardiovascular disease and diabetes mellitus.
- Adult vaccination ecosystem building: Over the last 2–3 years, practitioner clinics and hospitals have seen a clear increase in adults seeking vaccination opinions; management's confidence in the ecosystem is improving with every passing quarter.
- Vaccine phasing issue: A couple of vaccines had availability phasing issues in Q1, expected to be corrected in Q2.
Akshikar: "We're selling upwards of 45,000, 50,000 doses now on a quarterly basis. And that goes back to what we had said a couple of years back. Given India's demographic, given the large number of 50 plus adults and underlying -- with underlying comorbidities especially cardiovascular, comorbidities including areas like diabetes mellitus. I think we see an incredible future in the coming months only to build on this trend."
General Medicines & Operating Model
- Core business remains the engine: General Medicines, the lion's share of the business, grew well in double digits; all brands grew better than the market, with IQVIA efficiency indices at 105–106 across the board.
- MR productivity improving: Blended average productivity reached ₹15–16 lakhs per rep, improving 5–6% in Q1.
- Headcount stable for now: The current 2,000 GenMeds plus 200 established vaccines people are deemed the right numbers; new recruitment will happen only in areas with little or no presence, such as liver disease, with the hematology team already recruited.
- Super-distributor for tail-end reach: Part of the portfolio is managed through a super-distributor arrangement for tail-end products, enabling access to mofussil interiors.
- Local manufacturing model: All GenMeds are manufactured locally through GSK's own Nashik factory plus 20 contract manufacturers, following a local-for-local model; no plans to locally manufacture anything beyond the current portfolio, and the EU/UK FTA has no immediate bearing.
Akshikar: "I think we're one of the few markets where we still have double-digit growth for our general medicines business. As we all know, our products are still relevant, they still create tremendous value for patients at large and they are not only brands here, as I always say, they are trust marks in terms of the value that they bring in."
Margins, Investment & Profitability
- EBITDA margin walk: Gross margin improved ~150 bps, helped by pricing and product mix, partially offset by hardening of costs on imported purchases due to rupee depreciation; EBITDA grew 17% vs sales growth of 15%, so margins expanded.
- Opex spike is phasing, not a run-rate change: The 36% YoY opex increase was deliberate front-loading of promotional and marketing investment, including 3,800 HCP events and international speaker meets, concentrated in Q1 ahead of the seasonally biggest September quarter.
- Investment spend focused: The ~1 percentage point increase in spend-to-sales ratio was entirely product-focused direct marketing spends behind new launches and core Gen Med brands.
- PAT one-off: Dividend payout from the 100% subsidiary Biddle Sawyer improved PAT growth to 24%; excluding this one-off, PAT growth would have been ~17%.
- Margin outlook: S&A ratios are expected to normalize to historical levels through the year; full-year EBITDA margins are expected to be roughly at last year's ~34% range.
Biswas: "We expect our S&A ratios to normalize to historical as you move through the year and EBITDA margins to be roughly what we were at last year in 34% kind of range."
Strategic Vision & Long-Term Bets
- ₹8,000 crore / 2x vision intact: The ambition remains undiluted, to be achieved by bolt-on growth platforms (oncology, innovative assets) layered on top of the established GenMeds and vaccines base growing at 8–10%.
- Upcoming launch pipeline: Blenrep, Ojjaara, and Arexvy are expected to come through potentially in the next 18–24 months; Jemperli additional indications in rectal cancer may yield news in the next 2–3 months, hopefully within this financial year or the first quarter of next year.
- Flu mRNA vaccine identified as a major opportunity: Management flagged the flu mRNA platform as one of the bigger opportunities GSK would pursue, while the 24-valent pneumococcal vaccine is not a key priority for the Indian market currently.
- Global restructuring context: GSK plc announced a restructuring program focused on unlocking inefficiencies and improving ways of working across functions and geographies; India's double-digit Gen Med growth makes it a differentiated market within the global portfolio.
- Single-minded growth focus: Management's overriding objective is sustaining double-digit top-line momentum in coming quarters; EBITDA is treated as an outcome, not the primary target, and no formal forward-looking guidance is given, though EBITDA margins are expected to be roughly at last year's 34% range.
Akshikar: "I think EBITDA is an outcome, our focus is to deliver that top-line growth. I think that's the single-minded focus that we have; the double-digit growth that I've talked about for the last few years is the single-minded objective we have."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Blenrep launch | Antibody drug conjugate for second-line refractory relapsed multiple myeloma | Q2 FY27, or Q3 at the latest (next 2–3 months) |
| Bepirovirsen launch | Functional cure for chronic hepatitis B, subject to trial outcomes | Still 3–4 quarters away at minimum |
| Full-year EBITDA margin | Roughly at last year's ~34% range | FY27 |
| S&A ratio normalization | Investment ratios to moderate and return to historical trends | Through the remaining quarters of FY27 |
| Vaccine phasing correction | Availability issues for a couple of vaccines to be resolved | Q2 FY27 |
| Jemperli additional indications | News on rectal cancer trials | Next 2–3 months, hopefully within FY27 or Q1 next year |
| Top-line growth objective | Sustain double-digit momentum; no formal forward guidance | Coming quarters |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹924 cr, +15% YoY; +4%–5% from favorable base effect, sustainable growth at 9%–10% |
| EBITDA growth | +17% YoY, two percentage points ahead of sales growth |
| EBITDA margin | Improved 50 bps YoY; gross margin up ~150 bps, spend-to-sales ratio up ~1 ppt |
| PAT | ₹253 cr, +24% YoY; +17% excluding one-off dividend from Biddle Sawyer subsidiary |
| PAT margin | 27.6%, expansion of 200 bps YoY |
| EPS | ₹14.95 for the quarter |
| Innovation portfolio share of revenue | 7% of total revenues, vs ~4% in Q1 FY26; contributed about 4 ppt of headline growth |
| Gross margin | Improved ~150 bps YoY, helped by pricing and product mix; partly offset by rupee depreciation on imports |
| Volume growth | ~3%–3.5% blended across entire business |
| Price growth | ~6% for the quarter |
| Shingrix growth | +65% YoY; crossed ₹100 cr on MAT basis; 45,000–50,000 doses sold in the quarter |
| Nucala new patient adds | ~100–120 patients per month, doubled from ~50–60 per month in Q1 FY26; ~600 patients on active treatment |
| Trelegy Ellipta monthly units | 10,000–12,000 units per month, holding share despite 10–12 generic launches |
| Oncology patients treated | ~260–270 patients in Q1; Jemperli + Zejula combined ~250–300 patients per quarter |
| MR productivity | ₹15 lakhs–₹16 lakhs per rep blended average; improved 5%–6% QoQ |
| Opex growth | +36% YoY, driven by deliberate front-loading of ~3,800 HCP events and product-focused marketing investments |
| EBITDA margin outlook | ~34% for FY27, in line with last year (per management commentary) |